T1	PROC 47 126	Estudio en fase I/II de la seguridad, tolerabilidad, farmacocinética y eficacia
T2	CHEM 141 151	relatlimab
#1	AnnotatorNotes T2	C4724799; Relatlimab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 156 165	nivolumab
#2	AnnotatorNotes T3	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	LIVB 169 196	participantes pediátricos y
T5	Age 183 194	pediátricos
T6	LIVB 197 212	adultos jóvenes
T7	Age 197 212	adultos jóvenes
T8	DISO 217 243	linfoma de Hodgkin clásico
#3	AnnotatorNotes T8	C1333064; Classical Hodgkin's Lymphoma; Neoplastic Process
T9	DISO 246 264	linfoma no Hodgkin
#4	AnnotatorNotes T9	C0024305; Lymphoma, Non-Hodgkin; Neoplastic Process
T10	CHEM 323 332	nivolumab
#5	AnnotatorNotes T10	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T11	LIVB 336 361	participantes pediátricos
T12	Age 350 361	pediátricos
T13	LIVB 364 379	adultos jóvenes
T14	Age 364 379	adultos jóvenes
T15	DISO 384 391	linfoma
#6	AnnotatorNotes T15	C0024299; Lymphoma; Neoplastic Process
T16	DISO 430 456	Linfoma de Hodgkin clásico
#7	AnnotatorNotes T16	C1333064; Classical Hodgkin's Lymphoma; Neoplastic Process
T17	DISO 459 477	linfoma no Hodgkin
#8	AnnotatorNotes T17	C0024305; Lymphoma, Non-Hodgkin; Neoplastic Process
T18	DISO 528 554	Linfoma de Hodgkin clásico
#9	AnnotatorNotes T18	C1333064; Classical Hodgkin's Lymphoma; Neoplastic Process
T19	DISO 557 575	linfoma no Hodgkin
#10	AnnotatorNotes T19	C0024305; Lymphoma, Non-Hodgkin; Neoplastic Process
T20	LIVB 604 632	Participantes de ambos sexos
T21	Age 633 651	menores de 18 años
T22	Age 685 711	igual o inferior a 30 años
T23	DISO 726 729	LHc
T24	LIVB 731 738	cohorte
#11	AnnotatorNotes T24	C0599755; Cohort; Population Group
T25	DISO 744 747	LNH
#12	AnnotatorNotes T25	C0024305; Lymphoma, Non-Hodgkin; Neoplastic Process
T26	LIVB 749 756	cohorte
#13	AnnotatorNotes T26	C0599755; Cohort; Population Group
T27	LIVB 767 780	Participantes
T28	PROC 819 841	anatomopatológicamente
T29	Neg_cue 854 865	ausencia de
T30	Negated 866 875	respuesta
T31	PROC 890 927	tratamiento estándar de primera línea
T32	PROC 940 944	QTDA
T33	PROC 948 952	TACM
T34	LIVB 956 969	Participantes
T35	PROC 1008 1030	anatomopatológicamente
T36	Neg_cue 1042 1053	ausencia de
T37	Negated 1054 1063	respuesta
T38	PROC 1078 1106	tratamiento de primera línea
#14	AnnotatorNotes T38	C1708063; First line treatment; Therapeutic or Preventive Procedure
T39	LIVB 1113 1126	participantes
T40	DISO 1139 1157	enfermedad medible
#15	AnnotatorNotes T40	(C1513041 Measurable Disease)
T41	PROC 1173 1184	TEP-FDG-TAC
T42	LIVB 1192 1200	cohortes
#16	AnnotatorNotes T42	C0599755; Cohort; Population Group
T43	DISO 1204 1207	LHc
T44	DISO 1210 1213	LNH
#17	AnnotatorNotes T44	C0024305; Lymphoma, Non-Hodgkin; Neoplastic Process
T45	PROC 1243 1254	Tratamiento
#18	AnnotatorNotes T45	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T46	CHEM 1269 1336	anticuerpo contra la proteína 4 asociada a linfocitos T citotóxicos
T47	CHEM 1355 1365	anticuerpo
#19	AnnotatorNotes T47	C0003241; Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T48	PROC 1504 1516	tratamientos
#20	AnnotatorNotes T48	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T49	Negated 1504 1516	tratamientos
T50	CHEM 1529 1536	PD(L)-1
T51	PROC 1540 1551	Tratamiento
#21	AnnotatorNotes T51	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T52	CHEM 1563 1571	fármacos
#22	AnnotatorNotes T52	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T53	CHEM 1584 1589	LAG-3
T54	LIVB 1593 1606	Participantes
T55	PROC 1611 1647	trasplante autólogo de células madre
#23	AnnotatorNotes T55	 autologous blood donor, stem cells C3650129
T56	PROC 1649 1653	QTDA
T57	PROC 1654 1658	TACM
T58	LIVB 1670 1683	Participantes
T59	PROC 1704 1732	alotrasplante de médula ósea
#24	AnnotatorNotes T59	Autologous bone marrow transplant C0194037
T60	DISO 1735 1771	enfermedad de injerto contra huésped
#25	AnnotatorNotes T60	C0018133; Graft-vs-Host Disease; Disease or Syndrome
T61	DISO 1773 1777	EICH
#26	AnnotatorNotes T61	C0018133; Graft-vs-Host Disease; Disease or Syndrome
T62	DISO 1812 1816	EICH
#27	AnnotatorNotes T62	C0018133; Graft-vs-Host Disease; Disease or Syndrome
T63	LIVB 1832 1845	Participantes
T64	DISO 1850 1873	enfermedades sistémicas
#28	AnnotatorNotes T64	C0442893; Systemic disease; Disease or Syndrome
T65	Neg_cue 1902 1904	no
T66	Negated 1905 1917	relacionadas
T67	DISO 1925 1931	cáncer
#29	AnnotatorNotes T67	C0006826; Malignant Neoplasms; Neoplastic Process
T68	LIVB 1957 1971	investigadores
#30	AnnotatorNotes T68	C0035173; Research Personnel; Professional or Occupational Group
T69	Spec_cue 1980 1993	comprometería
T70	Speculated 1997 2006	capacidad
T71	LIVB 2011 2023	participante
T72	Speculated 2029 2036	tolerar
T73	PROC 2040 2051	tratamiento
#31	AnnotatorNotes T73	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T74	LIVB 2067 2080	Participantes
T75	DISO 2085 2111	enfermedad autoinmunitaria
#32	AnnotatorNotes T75	C0004364; Autoimmune Diseases; Disease or Syndrome
T76	CHEM 308 318	Relatlimab
T77	DISO 974 977	LNH
T78	DISO 785 788	LHc
T79	Neg_cue 1487 1499	excepción de
T80	CHEM 1368 1478	fármaco dirigido específicamente a la coestimulación de los linfocitos T o a las vías de los puntos de control
T81	Observation 265 276	recurrentes
T82	Observation 279 290	resistentes
T83	Observation 478 489	recurrentes
T84	Observation 492 503	resistentes
T85	Observation 789 792	R/R
T86	Observation 796 807	alto riesgo
T87	Observation 866 875	respuesta
T88	Observation 878 885	fracaso
T89	Observation 978 981	R/R
T90	Observation 985 996	alto riesgo
T91	Observation 1054 1063	respuesta
T92	Observation 1066 1073	fracaso
T93	Result_or_Value 1158 1166	positiva
T94	Quantifier_or_Qualifier 1572 1589	dirigidos a LAG-3
T95	Quantifier_or_Qualifier 1779 1785	activa
T96	Quantifier_or_Qualifier 1820 1828	grado >2
T97	Quantifier_or_Qualifier 1874 1901	clínicamente significativas
T98	Observation 1997 2006	capacidad
T99	Observation 2029 2036	tolerar
T100	Patient 169 194	participantes pediátricos
T101	Patient 197 212	adultos jóvenes
T102	Patient 336 361	participantes pediátricos
T103	Patient 364 379	adultos jóvenes
T104	Patient 604 632	Participantes de ambos sexos
T105	Patient 731 738	cohorte
T106	Patient 749 756	cohorte
T107	Patient 767 780	Participantes
T108	History_of 890 901	tratamiento
T109	Patient 956 969	Participantes
T110	History_of 1078 1106	tratamiento de primera línea
T111	Patient 1113 1126	participantes
T112	Patient 1192 1200	cohortes
T113	History_of 1243 1254	Tratamiento
T114	History_of 1269 1279	anticuerpo
T115	History_of 1355 1365	anticuerpo
T116	History_of 1368 1478	fármaco dirigido específicamente a la coestimulación de los linfocitos T o a las vías de los puntos de control
T117	History_of 1540 1551	Tratamiento
T118	History_of 1563 1590	fármacos dirigidos a LAG-3.
T119	Patient 1593 1606	Participantes
T120	History_of 1611 1647	trasplante autólogo de células madre
T121	History_of 1649 1653	QTDA
T122	History_of 1654 1658	TACM
T123	Patient 1670 1683	Participantes
T124	History_of 1704 1732	alotrasplante de médula ósea
T125	History_of 1735 1763	enfermedad de injerto contra
T126	Patient 1764 1771	huésped
T127	History_of 1773 1777	EICH
T128	History_of 1812 1816	EICH
T129	Patient 1832 1845	Participantes
T130	Other 1957 1971	investigadores
T131	Patient 2011 2023	participante
T132	Patient 2067 2080	Participantes
